We demonstrate the role of p53 mediated caspase-2 activation in the mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-treated renal tubular epithelial cells (RTEC). Gene silencing of AIF with its siRNA (small interference RNA) suppressed cisplatin-induced AIF expression and provided a marked protection against cell death. Subcellular fractionation and immunofluorescence studies revealed cisplatininduced translocation of AIF from the mitochondria to the nuclei. Pancaspase inhibitor Z-VAD-fmk or p53 inhibitor pifithrin-α prevented mitochondrial release of AIF suggesting that caspases and p53 are involved in this release. Caspase-2 and -3 that were predominantly activated in response to cisplatin provided a unique model to study the role of these caspases in AIF release. Cisplatintreated caspase-3 (+/+) and caspase-3 (-/-) cells exhibited similar AIF translocation to the nuclei suggesting that caspase-3 does not affect AIF translocation and thus, caspase-2 may be involved in the translocation. Caspase-2 inhibitor Z-VDVAD-fmk or downregulation of caspase-2 by its siRNA significantly prevented translocation of AIF. Caspase-2 activation was a critical response from p53 which was markedly induced and phosphorylated in cisplatin-treated cells. Overexpression of p53 not only resulted in caspase-2 activation but also mitochondrial release of AIF. The p53 inhibitor pifithrin-α or p53 siRNA prevented both cisplatin-induced caspase-2 activation and mitochondrial release of AIF. Caspase-2 activation was dependent on the p53-responsive gene, Pidd, a death-domain containing protein that was induced by cisplatin in a p53-dependent manner. These results suggest that caspase-2 activation mediated by p53 is an important pathway involved in the mitochondrial release of AIF in response to cisplatin injury.
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INTRODUCTION
Apoptosis-inducing factor (AIF) is a highly conserved mitochondrial inter-membrane flavoprotein encoded by nuclear DNA (1, 2) . In response to a specific apoptotic stimulus, AIF is translocated to the cytosol and then to the nucleus. When in the nucleus, AIF associates with chromatin (3) and the nuclear protein cyclophilin A (4). This interaction enables AIF to induce nuclear chromatin condensation and large-scale DNA fragmentation (2, 5) . AIF without these interactions loses its ability to degrade DNA (4) . In addition to its endonuclease function in apoptosis, AIF has NADH oxidase activity confined to the mitochondria in normal cells (1) . Recently, AIF has also been shown to participate in the respiratory chain complex I activity (6) .
Overexpression of recombinant AIF by transient transfection, microinjection, or by adenoviral infection, results in chromatinolysis and cell death without caspase activation (1, 7, 8) . However, the question of whether the release of mitochondrial AIF into the cytosol and the nucleus is dependent on caspase activation is not fully resolved. The release of AIF has been shown to be caspase-independent in some cell types (9) . These studies were supported by the evidence that caspase inhibitors (10, 11) and Apaf-1 or caspase-3 deficient neuronal and mouse embryonic fibroblasts (MEFs) cells were unable to prevent mitochondrial release of AIF in response to death signals (7, 12) . These studies suggest that AIF translocation is independent of caspase-9 and caspase-3 activation in these cells. However, recent evidence has also suggested the role of caspases in the mitochondrial release of AIF. Mitochondrial release of AIF was blocked by pancaspase inhibitor in He La and Jurkat cells treated with staurosporin or actinomycin D (13, 14) . In response to an apoptotic stimulus many mitochondrial inter-membrane proteins including cytochrome c, Smac/Diablo, Omi/HtrA2, Endo G, and AIF are released on permeabilization of the mitochondrial outer membrane. Although proapoptotic molecules of the Bcl-2 family can regulate the mitochondrial permeabilization (15, 16) little is known on the mechanism and the temporal sequence of the release of the mitochondrial inter-membrane proteins. Recent evidence showed that the mitochondrial membrane permeabilization induced by Bax/Bak or tBid resulted in selective release of cytochrome c, Smac/Diablo and Omi/HtrA2 (14, 17) but not AIF, and subsequent caspase activation was required for the mitochondrial release of AIF (14) . The identity of caspase involved in the release of AIF was not determined in these studies.
Nephrotoxicity is one of the major side effects when the chemotherapeutic drug cisplatin is used for the treatment of solid tumors of a wide range of tissues (18, 19) . The cellular and molecular mechanisms responsible for druginduced nephrotoxicity are not well understood. Mitochondrial dysfunction is an important component of cisplatin nephrotoxicity to proximal tubules in vivo (20) (21) (22) (23) and in vitro (24) (25) (26) . Cisplatin has been shown to induce the mitochondrial release of proapoptotic molecules including cytochrome c (27) (28) (29) (30) (31) , Omi/HtrA2, (32), Smac/Diablo (33), and AIF (11) . The cisplatininduced mitochondrial-dependent intrinsic pathway of caspase activation and cell death was blocked significantly by caspase inhibitors in many cell types (34) (35) (36) (37) (38) . However, the mechanism of cisplatin-induced mitochondrial release of AIF and the role of caspases in its release is not known. We have recently demonstrated a marked increase in cisplatin-induced caspase-3 and -2 activation in renal tubular epithelial cells (RTEC) (39) . This study in RTEC provided us a unique model to examine the role of caspase-2 and -3 in the mitochondrial release of AIF. Thus, in the present study we have explored cisplatin-induced release of mitochondrial AIF to the cytosol and the nucleus, and the role of caspases in this process. We provide evidence that cisplatin-induced caspase-2 activation but not caspase-3 activation is involved in the mitochondrial release of AIF. We have further explored the mechanism of caspase-2 activation and demonstrated the role of p53 and its responsive gene PIDD (p53 induced death domain protein) on caspase-2 activation that participates in the subsequent release of mitochondrial AIF in RTEC.
MATERIALS AND METHODS

Cell Culture and Reagents
LLC-PK 1 cells obtained from American Type Culture Collection (ATCC) were cultured as described in our previous studies (39) . The cells were grown in ATCC Medium 199 supplemented with 10% heat-inactivated fetal calf serum. Cultures were maintained in a humidified incubator gassed with 5% CO 2 and 95% air at 37° C and fed with fresh medium at intervals of 48 h-72 h. Experiments were performed with cells grown to 80% confluence. Caspase substrates were purchased from Peptide International (Louisville, KY) and antibodies to caspase-3, AIF, histone H1A, α-tubulin, β-actin, and proteins of the Bcl-2 family were from Santa Cruz Biotechnology (Santa Cruz, CA) Antibodies to p53, Ser-15-phosphorylated p53, and active caspase-3 were obtained from Cell Signaling Technology (Beverly, MA). Antibody to Cox IV (cytochrome c oxidase subunit IV) was from Molecular Probes (Eugene, OR). Caspase inhibitors, benzyloxycarbonyl-Val-Ala-Aspfluoromethylketone (Z-VAD-fmk), benzyloxycarbonyl-Val-Asp-Val-Ala-Aspfluoromethylketone (Z-VDVAD-fmk), and benzyloxycarbonylAsp-Glu-Val-Aspfluoromethylketone (Z-DEVD-fmk) were obtained from Enzyme System Products (Livermore, CA).
Induction of Cisplatin-Induced Injury
The cell culture medium was replaced with fresh medium containing serum and cells were incubated either without or with cisplatin at various concentrations (25 µM-200 µM) for the period of time indicated (1 h-24 h). In initial studies we determined the optimum exposure time and the suitable concentration of cisplatin. To determine the effect of inhibitors, cells were treated with the inhibitors for 10 min prior to the addition of cisplatin (50 µM).
Preparation of Primary Cultures of Caspase-3 (-/-) and Wild-type (+/+) RTEC
Primary cultures of renal tubular epithelial cells (RTEC) were prepared from caspase-3 (-/-) and wild-type (+/+) mice. Caspase-3 (-/-) mice were generously provided by Richard Flavell, Ph.D. All procedures for the preparation of primary cultures were performed under sterile conditions as described (40) . Briefly, renal cortices were minced and incubated with 0.5 mg/ml collagenase and 0.5 mg/ml soybean trypsin inhibitor for 30 min. After the removal of large, undigested fragments by gravity, the cell suspension was washed first with Hank's solution containing 10% horse serum and then with Dulbecco's modified Eagle's medium (DMEM) by centrifugation, and the cell pellets were suspended in growth medium containing a serumfree mixture of DMEM, Ham's F-12 (1:1), 2 mM glutamine, 15 mM HEPES, 5 µg/ml transferrin, 5 µg/ml insulin, 50 mM hydrocortisone, 500 U/ml penicillin, and 50 mg/ml streptomycin. The cells previously isolated by this procedure were identified as being predominantly of proximal tubular origin (41). The cell suspension was then plated into tissue culture flasks. After 24 h, the monolayers were washed several times to remove unattached cells and new growth medium was added. The cultures become confluent in 5-7 days. Subcellular Fractionation Isolation of nuclear fraction: The nuclei were prepared by a minor modification of the previously described procedure (42) . LLC-PK1 cells were gently scraped using the rubber policeman, harvested by centrifugation, and washed twice with PBS. The cells were resuspended in homogenization buffer (HB) containing 210 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.5, and supplemented with 1x protease inhibitor cocktail (Sigma) and homogenized with 30-35 strokes of a Dounce homogenizer (Wheaton, USA). To establish the number of stokes for cell permeabilzation, the trypan blue exclusion method (0.4% trypan blue solution in PBS diluted 1:10 with cell suspension) which discriminates between permeabilized (stained) cells and intact cells (unstained) was used. The suspension was then transferred to Eppendorf centrifuge tubes and centrifuged at 500g for 10 min to pellet nuclei and unbroken cells. The nuclear fraction was adjusted to the final concentration of 0.25 M sucrose and 0.35 % Triton X-100 and layered on top of a discontinuous sucrose density gradient prepared with 0.32 M, 0.8 M and 1.2 M sucrose in Beckman centrifuge. The tubes were centrifuged at 40,000 g for 2 hours. The nuclei were recovered at the interface of 0.8 M and 1.2 M sucrose. Samples were stored at -70ºC before being used for Western blot analysis. Isolation of Mitochondria: Mitochondria were isolated by sucrose density gradient centrifugation essentially as described (43). Briefly, cells were washed with PBS containing 1 mM EDTA and resuspended in isotonic HB supplemented with 1x protease inhibitor cocktail (Sigma). Cells were broken with 30-35 strokes of a Dounce homogenizer (Wheaton, USA) and the suspension was centrifuged at 2,000 g in an Eppendorf centrifuge at 4°C. The supernatant was then centrifuged at 13,000 g at 4°C for 10 min. The pellet was resuspended in 1 ml of HB and layered on top of a discontinuous sucrose gradient consisting of 20 ml of 1.2 M sucrose, 10 mM HEPES, pH 7.5, 1 mM EDTA, and 0.1% BSA on top of 17 ml of 1.6 M sucrose, 10 mM HEPES, pH 7.5, 1 mM EDTA, and 0.1% BSA. The samples were centrifuged at 27,000 rpm for 2 h at 4°C using a Beckman SW28 rotor. Mitochondria recovered at the 1.6-1.2 M sucrose interface were washed and resuspended in HB. This procedure results in the mitochondrial preparation with very little contamination of other organelles. Contamination of mitochondria in the nuclear fraction was determined by immunoblotting for cytochrome oxidase subunit IV, an integral membrane protein of the mitochondria.
Immunofluorescence Localization of AIF and Caspase-3
Cells were grown on sterile glass cover slips and treated with cisplatin for various time points in the presence and absence of inhibitors. Following treatments, the cells were washed in PBS and fixed in 2% parformaldehyde in PBS for 15 min. After washing twice in PBS the cells were permeabilized for 1 h in blocking buffer containing 1% BSA, 1% goat serum, 0.1% saponin, 1 mM CaCl 2 , 1 mM MgCl 2 , and 2 mM NaV 2 O 5 in PBS. The cells were then incubated with mouse monoclonal anti-AIF antibody (1:200) and rabbit anti-caspase-3 (active) antibody (1:200) for 1h in a 37 o C humidified incubator. After three washes in washing buffer containing 1% BSA and 0.1% saponin in PBS the cells were incubated at 37 o C in a humidified incubator for 1h with 1:500 of Alexa fluor-conjugated secondary antibody (goat anti-mouse Alexa fluor 488 for AIF and goat anti-rabbit Alexa fluor 594 for caspase-3) in blocking solution and again washed with washing buffer. The nuclei were stained with 0.5 µg/ml of 4', 6'-diamidino-2-phenylindole (DAPI) for 5 min and the cells were washed twice in washing buffer. Cover slips were then mounted on slides using antifade mounting media (Molecular Probes). Localization of active caspase-3 and morphological changes of the nuclei were analyzed using a Zeiss Deconvoluted microscope.
Determination of Caspase-2 and Caspase-3 Activity
Cells were harvested by centrifugation and the pellets were washed in cold PBS twice. The washed cell pellets were lysed with 20 mM HEPES, pH 7.5, containing 10% sucrose, 0.1% CHAPS, 2 mM DTT, 0.1% NP40, 1 mM EDTA, 1 mM PMSF, 1µg/ml leupeptin and 1µg/ml pepstatin A at 4°C. The supernatants obtained were used to determine the activities of caspase-2, and -3 by fluorometric assay using the following amino-4-methyl coumarin (AMC)-tagged substrates: VDVAD-AMC for caspase-2 and DEVD-AMC for caspase-3 (45) . The enzyme extracts containing 50 µg protein were incubated with 100 mM HEPES, pH 7.4, containing 10% sucrose, 0.1% CHAPS, 10 mM DTT and 50 µM of caspase substrate in a total reaction volume of 0.25 ml. The reaction mixture was incubated for 60 min at 30°C. At the end of incubation, the amount of liberated fluorescent group, AMC was determined using a fluorescent spectrofluorometer (Perkin Elmer) with an excitation wavelength of 380 nm and an emission wavelength of 460 nm. AMC was used as a standard. Based on the standard curve made with fluorescence reading with free AMC, the data for caspase activity are expressed as nmoles of AMC liberated when 50 µg of protein extract was incubated with 50 µM of substrate for 60 min at 30°C.
Western Blot Analysis
The cell lysates were prepared as described above for caspase assay and equal amounts of protein samples were resolved by SDSpolyacrylamide gel electrophoresis using 8% polyacrylamide gels as previously described (44) . The proteins were electrophoretically transferred to a Transblot membrane (BioRad) and processed for immunoblotting with specific antibodies and detected using the ECL system as previously described (39) .
Adenoviral Infection of Cells
Recombinant adenoviral vectors carrying p53, GFP, lacZ, and AIF were generous gifts from Dr Ruth S. Slack. The amplification of packaged adenovirus was achieved by infection of HEK 293 cells. Adenoviruses were released from the cells by repeated freezing and thawing of the cells and a titer of 1.1x10 12 pfu /ml was produced. The adenoviral infectivity titers for LLC-PK1 cells were determined using procedures as described (46) . LLC-PK1 cells growing at 70-80% confluency were infected with adenoviral vectors at a multiplicity of infection (MOI) of 50 plaqueforming units/cell. The presence of the recombinant adenovirus was confirmed by Western blot. When the adenovirus was used for the experiment, the efficiency of the infection was confirmed by contransfection of Ad-GFP or AdLacZ followed by the X-Gal staining for beta-Gal expression. The cells were infected with adenovirus p53 or transfected with p53 siRNA 36 hours prior to the treatment of cisplatin.
ReverseTtranscription PCR (RT-PCR)
Total RNA from the cultured cells was obtained by using the RNeasy Mini Kit (Qiagen, Inc., Chatsworth, CA). Approximately 1 µg of total RNA was used for reverse transcription. The expression levels of various genes were determined by RT-PCR. The following primer pairs were used for amplifying gene-specific amplicons: GGAAGCTCAGGATGTTCGAG-3' and the complementary downstream primer 5'-GTTTCTGCATCACCCAGGTT-3' for PIDD, 5'-CAGCTCCAAGAGGTTTTTCG-3' and 5'-CCAGCATCACTCTCCTCACA-3' for caspase-2, and 5'-AGCCATGTACGTAGCCATCC-3' and downstream primer 5'-TCTCAGCTGTGGTGGTGAAG-3' for β-actin used as an internal control. To ensure that the PCR reaction had not reached a saturation point that would skew the quantitation, aliquots were removed after certain cycle numbers and analyzed in series on an agarose gel. Then the minimum cycle which initially gives optimal product was used in the experiment. RNA Interference LLCPK1 cells were plated in a 6-well plate with complete medium. When the cells were 60% confluent old medium was replaced with fresh medium without serum and antibiotics. Small interfering RNAs (siRNAs) were designed or obtained from commercial sources to interfere the expression of AIF, p53 and caspase-2. AIF siRNA sequence 5'-AUGCAGAACUCCAAGCACGTT -3' (sense strand) was designed using online software (BLOCK-iT™ RNAi Designer from Invitrogen). Commercially available siRNAs for AIF, caspase 2, p53 and AIF from Santa Cruz Biotechnology were also used in this study according to the manufacturer's instructions. Briefly, Lipofectamine (10 µl) and siRNA (10 pmol in 10 µl) in 0.5 ml of serum free media were mixed and incubated at RT for 20 min. The cells in each well were then transfected with this mixture. After 12h, FBS was added to a final concentration of 10 % and on day 2 the medium in the cells was replaced with fresh medium before cisplatin treatment. Cell Viability and Cell Death Assays Cells (5,000/well) were plated in 96-well dishes and treated with 25 µM caspase inhibitors (Z-VAD-fmk, or Z-VDVAD-fmk) or p53 inhibitor pifithrin-α prior to the treatment with 50 µM cisplatin. Inhibition of cell proliferation was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Roche Molecular Biochemicals Laval, PQ) according to manufacture's protocol. For the detection of apoptosis cells were grown on glass cover slips in six-well plates. The cells were treated with caspase inhibitors or pifithrin-α for 1 h prior to treatment with 50 µM cisplatin for 12h. Apoptosis was detected on the basis of nuclear morphology. Cells were fixed with 4% paraformaldehyde and stained with DAPI to reveal fragmented and condensed nuclei.
RESULTS
Translocation of Mitochondrial AIF to Nuclei
We have examined the role of AIF and its translocation during cisplatin injury to renal tubular epithelial cells (RTEC). AIF protein is constitutively expressed in RTEC and its basal expression was markedly increased by cisplatin injury in a time-and dose-dependent manner (Figure 1) . Downregulation of AIF with its siRNA provided marked protection against cisplatininduced cell death (Figures 2A, 2B , and 2C) when tested at multiple time points at 8 h, 12h, and 16 h following cisplatin treatment ( Figures  2C and 2D) . The effect of AIF siRNA was specific since scrambled siRNA did not change the expression of AIF. Also, AIF siRNA did not affect the expression of caspase-3 (Figure 2A ). Immunofluorescence analysis of control and cisplatin-treated cells revealed translocation of AIF from the mitochondria into the nuclei of many cells ( Figure 3 ). As shown, control cells reveal exclusively mitochondrial punctate staining for AIF. No nuclear staining for AIF or active caspase-3 was seen ( Figures 3A and 3B, panel;  control) . When cells were treated with cisplatin and co-immunostained with anti-AIF and antiactive caspase-3, a significant number of cells displayed nuclear staining for AIF as well as for active caspase-3 ( Figures 3A and 3B panel; Cisplatin) indicating translocation of AIF to the nuclei. Staining with DAPI revealed many condensed and fragmented nuclei. Most of these apoptotic nuclei displayed colocalization for AIF and active caspase-3 ( Figure 3A and 3B, panel; Cisplatin).
Z-VAD-fmk and Pifithrin-α Block AIF Translocation
To examine the role of caspases and p53 in AIF translocation we first determined the effect of their inhibition in the mitochondrial release of AIF. Prior treatment of pancaspase inhibitor Z-VAD-fmk in cisplatin treated cells did not show nuclear staining for AIF and active caspase-3. This suggests that Z-VAD-fmk was able to prevent AIF translocation to the nuclei as well as block caspase-3 activation and nuclear fragmentation (Figure 3A, panel; Cisplatin + ZVAD) . The p53 inhibitor pifithrin-α that blocks p53 transcriptional activity, showed the same effect as observed with Z-VAD-fmk, preventing the nuclear features of apoptosis, caspase activation, and translocation of AIF to the nucleus (Figure 3B , panel; Cisplatin + Pifithrin). Western blot analysis of the subcellular fractions also revealed translocation of AIF from the mitochondria to the nuclei ( Figure 3C) . In control cells, AIF was primarily present in the mitochondria and very little amount was detected in the cytosol and the nuclei. In cisplatin-treated cells, AIF was predominantly detected in the cytosol and the nuclei. Pancaspase inhibitor Z-VAD-fmk and p53 inhibitor pifithrin-α markedly prevented the release of AIF from the mitochondria to the cytosol and the nuclei. Blots for Cox IV, α-tubulin, and histone H1A were included to confirm equivalent loading for the mitochondrial, cytosolic, and nuclear fractions, respectively. There was some cross contamination which became evident when mitochondrial marker Cox IV was assessed in the nuclear fractions, and nuclear marker histone H1A was assessed in the mitochondrial fractions by immunoblotting (not shown). These studies further suggest that p53 and caspases may be involved in the translocation of AIF to the nucleus.
P53 Triggers Caspase-2 and Caspase-3 Activation and AIF Translocation
In response to a variety of death stimuli, p53 is stabilized and rapidly activated in many cell types (47, 48) . One important mechanism through which p53 promotes caspase activation is by transactivation of proapoptotic proteins that primarily involve the mitochondrial-dependent apoptotic pathway (48, 49) . Cisplatin treatment markedly induced p53 and its phosphorylation in RTEC ( Figure 4A, panel a) . Also, transfection of normal cells with a recombinant adenoviral vector carrying an expression cassette for p53 (Ad-53) increased expression of p53 as well as its phosphorylation ( Figure 4A, panel b) . Control Ad-LacZ transfection did not induce p53 expression (data not shown). To determine the role of p53 in cisplatin-induced caspase-2 and -3 activation we utilized p53 siRNA to downregulate p53 expression by RNA interference. The p53 siRNA efficiently and specifically silenced p53 expression ( Figure 4B, panel a) since p53 siRNA silenced p53-responsive p21 expression without affecting p73 expression ( Figure 4B, panel a) . Cisplatin-induced marked activation of caspase-3 and caspase-2 that we have previously shown in these cells (39) was significantly blocked by p53 siRNA as well as by the p53 inhibitor pifithrin-α ( Figure 4B, panel b) . To further ascertain whether p53 promotes caspase-2 and -3 activation, we transfected RTEC with Ad-p53 or the control AdLacZ. Overexpression of p53 with Ad-53 resulted in caspase-2 and -3 activation ( Figure 4B, panel  b) . In addition, overexpression of p53 resulted in marked AIF translocation and cell death that was effectively prevented by pifithrin-α and Z-VADfmk ( Figure 4C ). These studies indicate that p53 activation is involved upstream of the cisplatininduced caspase-2 and -3 activation and, is associated with AIF translocation and cell death.
Thus, it was of interest to examine whether caspase-3 and/or caspase-2 are involved in the translocation of AIF from the mitochondria to the nuclei.
Caspase-3-Deficient Cells Do Not Block AIF Translocation
To examine the role of caspase-3 in the translocation of AIF, we prepared primary cultures of kidney proximal tubular epithelial cells from caspase-3 (-/-) and caspase-3 (+/+) mice. Immunocytochemistry revealed cisplatin-induced translocation of AIF to the nuclei in both caspase-3 (+/+) ( Figure 5A ) and caspase-3 (-/-) cells (Figure 5B) suggesting that the knockout of the caspase-3 gene does not affect AIF translocation. Cisplatin caused cell death in both caspase-3 (+/+) and caspase-3 (-/-) cells. In addition, as revealed by DAPI staining, only caspase-3 (+/+) cells showed typical morphological changes associated with apoptosis including nuclear chromatin condensation and nuclear fragmentation. Unlike caspase-3 (+/+) cells, caspase-3 (-/-) cells showed nuclear condensation but no nuclear fragmentation implying that caspase-3 may be involved in the fragmentation of the nuclei. AIF staining was observed in all condensed nuclei in caspase-3 (-/-) cells. In fact, activation of caspase-3 was previously shown to cause an apoptotic nuclear morphology, which could be blocked by a peptide inhibitor of caspase-3 (50). The pancaspase inhibitor Z-VAD-fmk or pifithrin-α prevented transport of AIF to the nucleus in both caspase-3 (+/+) and caspase-3 (-/-) cells (Figures 5A and  5B) . These studies indicated that p53 controlled activation of caspase/s other than caspase-3 is involved in the translocation of AIF to the nucleus.
P53-responsive PIDD-mediated Caspase-2 Activation Involves in AIF Translocation
A recent study demonstrated that the p53 responsive gene PIDD is involved in caspase-2 activation (51). Caspase-2 activation requires the formation of a complex that contains the adapter protein RAIDD and a p53 responsive deathdomain containing protein PIDD (p53-induced protein with a death-domain). The overexpression of PIDD has been shown to result in spontaneous activation of caspase-2 (51). Thus, we examined PIDD expression in response to cisplatin injury to RTEC. In cisplatin-treated cells the p53 phosphorylation was followed by increased mRNA expression of PIDD. Pifithrin-α or p53 siRNA markedly reduced PIDD expression whereas overexpression of p53 with Ad-p53 elevated the levels of PIDD mRNA (Figure 6 ). These manipulations for p53 expression did not affect caspase-2 mRNA levels. These studies are in agreement of previous observation that p53 through its responsive gene PIDD can control activation of caspase-2. To examine the role of caspase-2 activation in AIF translocation we utilized its siRNA to downregulate caspase-2 expression (Figure 6a ) and used VDVAD-fmk to inhibit caspase-2 activity. Caspase-2 siRNA efficiently and specifically silenced caspase-2 expression but did not affect caspase-3 expression (Figure 6a) . Also, scrambled siRNA had no effect on caspase-2 and -3 expression. The inhibition of caspase-2 activity by VDVAD-fmk and the specific silencing of caspase-2 expression (Figure  7) prevented the translocation of AIF to the nucleus in RTEC (Figure 7) and markedly prevented cisplatin-induced cell death. Thus, p53 whose expression is upregulated in cisplatin injury to RTEC can mediate the release of AIF through the activation of caspase-2. Downregulation of caspase-2 with its siRNA provided marked protection against cisplatin-induced cell death ( Figures 7C, and 7D ) when tested at multiple time points at 8 h, 12h, and 16 h following cisplatin treatment.
DISCUSSION
In the present study we demonstrate that cisplatin injury to RTEC increased basal levels of AIF expression and induced translocation of AIF from the mitochondria to the nuclei. The inhibition of AIF by gene silencing with its siRNA significantly prevented cisplatin-induced cell death, suggesting that AIF plays an important role in renal tubular epithelial cell injury. Although cytochromec is also released in response to cisplatin, inhibition of cytochrome c mediated caspase-9 and caspase-3 activation provided only partial protection from cisplatin-induced apoptosis (39, 35, (52) (53) (54) suggesting the role of AIF in cell death.
Our results reveal that p53 is involved in the cisplatin-induced regulation of AIF translocation. In normal RTEC cells p53 is present at low levels and, following cisplatin treatment, wild-type p53 accumulates and become activated. The treatment of cells with the p53 inhibitor pifithrin-α markedly blocked AIF translocation. In addition, overexpression of p53 in RTEC induced AIF translocation and down-regulation of p53 using its siRNA suppressed AIF translocation. These studies further extend the previous observation that DNA damage-induced AIF translocation depends on the presence of p53 (10) .
We have previously shown that caspase-3 and caspase-2 are predominantly activated in cisplatin injury to RTEC (44) . We now demonstrate that the p53 inhibitor pifithrin-α or down-regulation of p53 by its siRNA not only significantly inhibited cisplatin induced caspase-2 and -3 activation but also blocked AIF translocation. Overexpression of p53 also induced activation of caspase-2 and -3 in RTEC. These studies suggest that p53 functions upstream of caspase-2 and -3 and is involved in regulation of cisplatin-induced caspase-2 and -3 activation.
It is well documented that p53 regulates transactivation of a multitude of proapoptotic genes that encode proteins for BH3-only proteins of the Bcl-2 family, death receptors, and other factors involved in different steps of the apoptotic pathway (55) . p53 can also regulate apoptosis by transcriptional repression of Bcl-2 and IAPs (56) . In addition, p53 has an extranuclear role to regulate transcription-independent apoptosis. The extranuclear p53 can directly activate Bax (57) or directly binds to Bclxl and Bcl-2 proteins to induce mitochondrial permeabilization and release cytochrome c (58). The p53 -responsive genes that control the expression of Bax, Bok, noxa, puma, apaf1, and p53AIP1 (59-61) can promote caspase-3 activation by induction of the mitochondrialdependent intrinsic apoptotic pathway. Thus, cisplatin-induced caspase-3 activation observed in RTEC can be attributed to p53 activation since p53 inhibitor or gene silencing of p53 in RTEC markedly prevent caspase-3 activation.
A recent study has demonstrated that p53 controls the expression of death-domain containing adaptor protein PIDD that, in association with another adaptor protein, RAIDD, recruit procaspase-2 by interaction with its prodomain (51) . The resulting ternary complex activates caspase-2 without interdomain cleavage of caspase-2 (51). Our studies show that the expression of the p53-responsive gene PIDD is induced by cisplatin as well as by overexpression of p53 in RTEC. Together, these studies suggest that p53 is involved in cisplatin-induced activation of caspase-2 and -3. Since p53 inhibition prevents translocation of AIF we hypothesized that p53-mediated caspase activation may play a role in AIF translocation. Indeed, the pancaspase inhibitor Z-VAD-fmk significantly blocked cisplatininduced translocation of AIF and provided marked protection in cisplatin-induced cell death. We further explored whether caspase-2 or -3 or both are involved in p53-dependent translocation of AIF.
The executioner caspase, caspase-3, is activated in cisplatin injury and p53 contributes significantly to this activation. However, caspase-3 activation is not involved in the translocation of AIF to the nuclei. This became evident from studies that demonstrated that AIF was translocated to the nucleus in primary caspase-3 (-/-) cells treated with cisplatin. Also, the caspase-3 inhibitor Z-DEVD-fmk did not prevent the translocation of AIF to the nucleus. These studies are in agreement with previous findings that show that apaf-1 (-/-) and caspase-3 (-/-) cells treated with apoptosis inducers staurosporine or etoposide did not prevent AIF release from the mitochondria (12) . Both p53 inhibitor and pancaspase inhibitor Z-VAD-fmk prevented translocation of AIF to the nucleus. These studies further support that p53-induced caspase-3 activation is not involved in translocation of AIF.
Our findings demonstrate that p53-mediated caspase-2 but not caspase-3 activation engage in the release of AIF. The specific function of caspase-2 to release AIF was confirmed by using a specific inhibitor of caspase-2 as well as by downregulating caspase-2 expression using caspase-2 siRNA. Several studies have provided compelling evidence that caspase-2 acts upstream of mitochondrial release of cytochrome c (62-67). Caspase-2, like caspase-8, is capable of cleaving the proapototic Bcl-2 family member Bid (65-67) that triggers mitochondrial membrane permeabilization. However, incubation of purified caspase-2 with isolated mitochondria can trigger the release of cytochrome c, AIF and Smac/Diablo independent of Bid and other cytosolic factors (67) , suggesting that caspase-2 can directly cause mitochondrial membrane permeabilization. Indeed, a recent study has demonstrated that caspase-2 directly permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids (62) .
In C. elegans, AIF homolog WAH-1 is released into the cytosol and nucleus by the BH3-domain protein EGL-1 in a caspase (CED-3)-dependent manner (68) . However, in mammalian cells, the dependence of caspases for AIF translocation is not well established and needs further exploration. Many studies are of the view that AIF mediates caspase-independent cell death (8, 9) whereas other recent studies show that AIF translocation to the nucleus is caspase-dependent (9, 13, 14) . The pancaspase inhibitor Z-VAD-fmk has been shown to prevent actinomycin-and staurosprine-induced AIF release and cell death in HeLa cells. A recent study showed that the pancaspase inhibitor prevented the actinomycinand staurosprine-induced mitochondrial release of AIF and Endo G but not cytochrome c, Smac/Diablo, and HtrA2/Omi in HeLa cells (7, 8). AIF release induced by introduction of cytochrome c into living Jurkat cells by squarewave pulse electropermeabilisation were prevented by Z-VAD-fmk (69), suggesting the involvement of caspases. Thus, more studies are required to resolve whether there are different mechanisms to release AIF from the mitochondria.
In summary, the data presented in the present study demonstrate that AIF translocation from the mitochondria to the nuclei plays an important role in cisplatin injury to RTEC. p53 is an essential mediator of AIF translocation to the nucleus in response to cisplatin in RTEC. Although cisplatininduced p53 plays a role in the activation of caspase-2 and -3, only caspase-2 is capable of mitochondrial release of AIF. The p53-responsive gene PIDD is involved in the mechanism of cisplatin-induced caspase-2 activation. Fig. 1 . AIF expression in response to cisplatin. Cells were treated with (A) 50 µM cisplatin (CP) for various time periods and (B) with various cisplatin concentrations ranging from 25 to 100 µM for 12 h as indicated. Cell lysates (50 µg protein) were analyzed for AIF expression by Western blot analysis using antibody to AIF. Blots for α-tubulin confirm equal loading of the samples. Fig. 2 . AIF siRNA provides marked protection from cisplatin-induced cell death. A. LLC-PK1 cells grown in six-well plates were transfected with AIF siRNA and treated with and without 50 µM cisplatin for 12 h as described in 'Materials and Methods'. Scrambled siRNA was used as a control. Cell lysates (50 µg protein) were analyzed for AIF, caspase-3, and β-actin by Western blot analysis using antibodies to AIF and β-actin, respectively. Caspase-3 was used to confirm specificity of AIF ablation. Anti-β-actin was used to confirm equal loading of the samples. B. MTT assays were used to determine the relative amounts of viable cells after down-regulation of AIF by its siRNA. Cells were treated with cisplatin (CP) at 8 h, 12 h, and 16 h following transfection with AIF siRNA as described in 'Materials and Methods'. Scrambled siRNA was used as a control. Results are mean ± SE (n=4, independent samples). * p < 0.01 is for AIF siRNA plus cisplatin vs 12 h cisplatin-treated cells. C. The appearance of apoptotic nuclei (fragmented and condensed nuclei) was scored by staining with DAPI after down-regulation of AIF by transfection with its siRNA. Percentage of apoptotic nuclei averaged from 20 fields visualized are shown. Scrambled siRNA was used as a control. Results are mean ± SE (n=4, independent samples). * p < 0.005 for cisplatin treated cells vs cisplatin plus AIF siRNA. Fig. 3A . Cisplatin induces AIF translocation to nucleus and Z-VAD-fmk prevents cisplatin-induced AIF translocation and nuclear fragmentation. Cells were untreated or treated with 50 µM cisplatin in the presence and absence of Z-VAD-fmk for 12 h. Cells were stained with anti-AIF (green) and anti-active caspase-3 (red) followed by DAPI (blue) for nuclei and images were overlaid as shown. Control group: control cells show clear staining with DAPI for intact nuclei (blue), clear punctate staining for AIF (green) exclusively in the mitochondria without nuclear staining, and no staining for active caspase-3. Cisplatin group: Cisplatin treated cells show many fragmented and condensed nuclear staining with DAPI (blue), prominent staining for nuclear AIF (green) that co-localizes with nuclei (blue), active caspase-3 (red) staining that localizes with nuclei (blue), and active caspase-3 (red) staining that co-localizes with nuclear AIF (green) which together appears as yellow. Cisplatin +ZVAD group: Prior treatment of pancaspase inhibitor does not show nuclear fragmentation and nuclear staining for AIF and caspase-3 in cisplatin-treated cells. * indicates view of the cisplatin-induced AIF and caspase-3 stained fragmented nuclei at higher magnification. Fig. 3B . p53 inhibitor pifithrin-α prevents cisplatin-induced AIF translocation and nuclear fragmentation. Cells were treated with 50 µM cisplatin in the presence and absence of pifithrin-α for 12 h. Cells were stained with anti-AIF (green) and anti-active caspase-3 (red) and DAPI (blue) for nuclei and images were overlaid as shown. As indicated p53 inhibitor pifithrin-α prevents nuclear localization of AIF, inhibits caspase-3 activation, and nuclear fragmentation. Control group: control cells show clear punctate staining for AIF exclusively in the mitochondria with no staining for AIF in the nuclei and no staining for active caspase-3. Cisplatin group: cisplatin-treated cells show prominent staining for nuclear AIF (green) and active caspase-3 (red). Yellow color indicates colocalization of AIF and active caspase-3 in the nuclei. Cisplatin + pifithrin-α group: pifithrin-α.-treated cells do not show nuclear fragmentation and nuclear staining for AIF and caspase-3. * indicates magnified view of the AIF and caspase-3 stained fragmented nuclei of cisplatin-treated cells shown in Cisplatin group. Fig. 3C . Analysis of the AIF translocation by subcellular fractionation. Cells were treated with 25 µM Z-VAD-fmk or pifithrin-α prior to the treatement with 50 µM cisplatin. Mitochondrial, cytosolic and nuclear fractions were isolated as described under 'Materials and Methods'and 10 µg of mitochondrial proteins, 10 µg of nuclear proteins and 50 µg of cytosolic proteins were electrophoresed and immunoblotted for AIF. Blots for Cox IV, α-tubulin, and histone H1A confirm equivalent loading for the mitochondrial, cytosolic and nuclear fractions, respectively. Fig. 4A . a. Cisplatin induces p53 and its activation. Cells were treated with 50 µM cisplatin for the time points indicated. Cell lysates (50 µg) were subjected to Western blot using antibodies specific to p53 and phospho-p53. b. Overexpression of p53 induces p53 activation. Cells were transfected with Ad-p53 in the presence and absence of 50 µM cisplatin and cell lysates (50 µg protein) were subjected to Western blot using antibodies specific to p53 and phospho-p53. Fig. 4B . cisplatin or p53 overexpression activates caspase-2 and -3, and p53 inhibition prevents cisplatin--induced caspase-2 and -3 activation. a. Cells were transfected with p53 siRNA as described in 'Materials and Methods' and cell lysates (50 µg protein) were electrophoresed and blotted for p53, p21, and p73. Transfection of p53 siRNA down-regulates p53 expression as well as its responsive p21 expression but not p73 expression. Blot for α-tubulin confirms equal loading of the samples b. Cells were treated with cisplatin or cisplatin plus pifithrin-α or infected with Ad -53 or infected with Ad-LacZ for control, or transfected with p53 siRNA as indicated and described in 'Materials and Methods'. The inhibition of p53 was accomplished by treatment with pifithrin-α or by transfection with p53 siRNA. Caspase-2 and -3 activities in cell lysates (50 µg protein) were determined using caspase-2 substrate VDVAD-AMC and caspase-3 substrate DEVD-AMC. Caspase activities are shown as relative units. The results are mean ± SE (n=4, independent samples). * p < 0.005 compared to cisplatin-treated cells. 
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